Short Interest in Pfizer Inc. (PFE) Grows By 19.3%

Pfizer Inc. (NYSE:PFE) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 59,697,345 shares, an increase of 19.3% from the November 30th total of 50,023,240 shares. Approximately 1.0% of the company’s stock are sold short. Based on an average trading volume of 18,934,861 shares, the days-to-cover ratio is currently 3.2 days.

Pfizer (NYSE:PFE) opened at $36.71 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $218,820.00, a P/E ratio of 22.52, a P/E/G ratio of 2.42 and a beta of 1.01. Pfizer has a 12-month low of $30.90 and a 12-month high of $37.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the business earned $0.61 earnings per share. equities analysts predict that Pfizer will post 2.59 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.70%. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is currently 78.53%.

Pfizer declared that its Board of Directors has authorized a stock repurchase plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. In the last three months, insiders sold 29,450 shares of company stock valued at $1,065,220. Corporate insiders own 0.06% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Holderness Investments Co. increased its position in shares of Pfizer by 29.7% in the first quarter. Holderness Investments Co. now owns 86,462 shares of the biopharmaceutical company’s stock valued at $2,958,000 after buying an additional 19,824 shares in the last quarter. State of Wisconsin Investment Board increased its position in shares of Pfizer by 4.4% in the first quarter. State of Wisconsin Investment Board now owns 5,994,405 shares of the biopharmaceutical company’s stock valued at $205,069,000 after buying an additional 251,287 shares in the last quarter. Thompson Davis & CO. Inc. increased its position in shares of Pfizer by 11.5% in the first quarter. Thompson Davis & CO. Inc. now owns 8,645 shares of the biopharmaceutical company’s stock valued at $296,000 after buying an additional 891 shares in the last quarter. Smith Moore & CO. increased its position in shares of Pfizer by 7.2% in the first quarter. Smith Moore & CO. now owns 38,130 shares of the biopharmaceutical company’s stock valued at $1,304,000 after buying an additional 2,575 shares in the last quarter. Finally, Segment Wealth Management LLC increased its position in shares of Pfizer by 1.4% in the first quarter. Segment Wealth Management LLC now owns 114,907 shares of the biopharmaceutical company’s stock valued at $3,931,000 after buying an additional 1,539 shares in the last quarter. Institutional investors own 69.75% of the company’s stock.

PFE has been the subject of several research analyst reports. BMO Capital Markets set a $37.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 10th. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. Pfizer currently has a consensus rating of “Buy” and an average price target of $38.77.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2018/01/04/short-interest-in-pfizer-inc-pfe-grows-by-19-3.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply